Neurology
Dual-Targeting Mechanism Achieves Lesion Suppression but Severe Hepatotoxicity Precludes Frontline Utility
Phase 3 data demonstrates fenebrutinib effectively halts acute peripheral inflammation, but the therapeutic window is aggressively narrowed by drug-induced liver injury risks and necessary hepatic monitoring protocols. See Disclaimer below * The global Relapsing Multiple Sclerosis (RMS) market operates as a massive commercial theater, encompassing approximately 800,000 prevalent patients in